Sign in

Nieves Martinez Lago

@dramartinezlago.bsky.social
204 followers 456 following 6 posts

Medical Oncologist & Clinical Researcher | Gastrointestinal Oncology · Neuroendocrine Tumors · Sarcomas | Real-World & Translational Research | @oncomet_ #MedSky #OncSky #NETsSky

PostsRepliesMedia
Reposted by Nieves Martinez Lago
American Society of Clinical Oncology @ascocancer.bsky.social · 11/03/2026
We've updated Patient-Clinician Communication guidelines. New recommendations cover: 💬 Core communication skills 🔎 Prognosis & treatment selection 🫶 End-of-life care 🥼 Clinician training Improving the dialogue for better cancer care. Read the update: bit.ly/3NnMnMR
024
Reposted by Nieves Martinez Lago
ESMO - European Society for Medical Oncology @myesmo.bsky.social · 06/03/2026
Do you have an impactful research idea? One that could improve care or advance science? Apply for the ESMO Leadership & Career Development Award, offering protected research time, leadership & communication training by 3 May 26 . 🔗https://ow.ly/Gicm50YqcbZ #Oncology #ESMOYOC
156
Reposted by Nieves Martinez Lago
OncoDaily @oncodaily.bsky.social · 11/03/2025
PEM in MSI and dMMR advanced solid tumors - Nieves Martinez Lago @dramartinezlago.bsky.social oncodaily.com/science/2541... #Cancer #CancerResearch #SolidTumor #ClinicalTrial #Medicine #Health #Oncology #OncoDaily
oncodaily.com
Nieves Martinez Lago: PEM in MSI and dMMR advanced solid tumors - OncoDaily
Nieves Martinez Lago: PEM in MSI and dMMR advanced solid tumors / Aurélien Marabelle, cancer, fight against cancer, Global fight against cancer, Nieves
0112
Reposted by Nieves Martinez Lago
Yüksel Ürün @yukselurun.bsky.social · 21/12/2024
📢 FDA grants accelerated approval to encorafenib + cetuximab + mFOLFOX6 for treatment-naïve mCRC with BRAF V600E mutation. BREAKWATER trial shows 61% ORR! Median DoR: 13.9 months. Most common toxicities: neuropathy, nausea, fatigue. @oncoalert.bsky.social @fda.gov @oncbrothers.bsky.social
0114
Reposted by Nieves Martinez Lago
Julie Hallet, MD MSc @halletjulie.bsky.social · 11/12/2024
🔑 concepts in #NETs surgery Mesenteric nodal disease classification👉🏻4 levels 4⃣ - unresectable 1⃣2⃣3⃣ - need tailored mesentery resection to spare bowel ✅Resectable if can salvage >=2 proximal SMA branches 📝 tinyurl.com/2w952fjv #NETSky #HPBSky #SurgSky #OncSky
1114
Reposted by Nieves Martinez Lago
Thor Halfdanarson @oncothor.bsky.social · 22/11/2024
Where should we place cabozantinib in the treatment algorithm of patients with NETs. Excellent review by Dr. Bhavana Konda from Ohio State University. #NANETS24 #NETsSky
0112
Reposted by Nieves Martinez Lago
Thor Halfdanarson @oncothor.bsky.social · 22/11/2024
Is PRRT safe in patients with NETs and extensive bone metastases…? Excellent presentation by Dr. Osama Mosalem at Mayo Florida @nanets.bsky.social 2024. Higher G3/G4 heme tox (29%), some persistent heme tox but no signal of increase in treatment related myeloid neoplasia. #NANETS24 #NETsSky #OncSky
2106
Reposted by Nieves Martinez Lago
Julie Hallet, MD MSc @halletjulie.bsky.social · 22/11/2024
Next big things in #NETs care @cives_mauro at #NANETS24 ▪️new PRRT regimens: alpha-emiting RLT ▫️BiTEs for NEC ▪️❓CAR T cell therapy ▫️tumor vaccines 💉 @nanets.bsky.social @oncothor.bsky.social #NETsSky #MedSky
0104
Nieves Martinez Lago @dramartinezlago.bsky.social · 18/11/2024
PD-L1 thresholds predict efficacy of ICI in 1L treatment of advanced GEA. A systematic review and meta-analysis of 7 phase III randomized trials 👉Optimal CPS cut-off is uncertain. 👉PD-L1 CPS ≥5 is a good cut-off to predict benefit from ICI. doi.org/10.1016/j.es...
020
Nieves Martinez Lago @dramartinezlago.bsky.social · 18/11/2024
El próximo 29 y 30 de noviembre tendrá lugar la XII Reunión del Grupo Gallego de investigación en Tumores Digestivos @Grupo_GITUD. Os esperamos en a Sede Afundacion de Ferrol.
010
Nieves Martinez Lago @dramartinezlago.bsky.social · 18/11/2024
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm 👉 FTD/TPI+BEV, REG and FRU for unselected pts 👉 Targeted Therapies for pts With Oncogenic Driver Molecular Alterations 👉Rechallenge antiEGFR in pts ctDNA RAS/BRAFwt www.nature.com/articles/s41...
nature.com
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm - Nature Reviews Clinical Oncology
Over the past few years, several novel therapies, including targeted therapies for specific subgroups as well as several non-targeted therapies, have been developed and approved for patients with chem...
010
Reposted by Nieves Martinez Lago
Thor Halfdanarson @oncothor.bsky.social · 17/11/2024
Must read for NET providers - the CommNETs/NANETS statement on NET biomarkers. An extremely useful document, detailing the clinical utility of NET biomarkers after thorough review of the evidence. The short of it is that most are not recommended for routine use. jamanetwork.com/journals/jam...
jamanetwork.com
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs
This study provides a guidance document to educate clinicians and patients on biomarkers informing prognosis and treatment in unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms...
042
Reposted by Nieves Martinez Lago
Thor Halfdanarson @oncothor.bsky.social · 17/11/2024
You unsure of how to monitor responses in NET patients after PRRT? All these different scans and blood tests confusing? Worry not, this team has you covered... A must read for all involved in radioligand therapy. #NETsSky #OncSky onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
<em>Journal of Neuroendocrinology</em> | BSN Journal | Wiley Online Library
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for both oncological and hormone control and is a widely accepted standard of care treatment for patients with neuroendocrine ne...
052
Nieves Martinez Lago @dramartinezlago.bsky.social · 17/11/2024
Adjuvant NIVO+IPI in pts with resected GC and GEJ following preoperative CT with high risk for recurrence (ypN+ and/or R1): VESTIGE study, phase 3. 👉mDFS nivo+ipi 11.4 vs CT 20.8m (HR 1.55; p=0.99) 👉12mDFS 47.1% vs 64.0% Give adjuvant FLOT even when there's residual cancer. doi.org/10.1016/j.an...
000
Nieves Martinez Lago @dramartinezlago.bsky.social · 17/11/2024
Ramucirumab/paclitaxel as switch maintenance vs continuation of FOLFOX after 3 months of FOLFOX in HER2-negative GC/GEJ cancer @TheLancetOncol doi.org/10.1016/S1470-… 🔎ARMANI phs 3 👉mPFS 6·6 vs 3·5 mo 👉mOS 12·6 vs 10·4 mo 🧐switch maintenance could be an option for pts not eligible for ICI/🎯💊
011
Nieves Martinez Lago @dramartinezlago.bsky.social · 17/11/2024
Hi! I’m Dr. Nieves Martínez Lago, a Medical Oncologist focused on GI, NET and endocrine tumors. I’m passionate about sharing knowledge and connecting with other professionals. Looking forward to engaging in insightful discussions and expanding my network. Feel free to reach out! #medsky #oncsky
030
Reposted by Nieves Martinez Lago
Thor Halfdanarson @oncothor.bsky.social · 16/11/2024
Here is a common problem in GI oncology, neuroendocrine differentiation (NED) in non-neuroendocrine carcinoma. According to many studies, outcomes are worse if NED is present (colorectum, esophagus, stomach, lung...). I get asked this often... #NETsSky #OncSky onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
Neuroendocrine differentiation and serotonin expression in oesophageal adenocarcinomas after neoadjuvant therapy: correlation with clinicopathological features and outcome
Expression of neuroendocrine markers in oesophageal adenocarcinoma after neoadjuvant chemoradiation is independently associated with reduced overall survival. Assessment of neuroendocrine differentia....
2103